Ema: "On Johnson & Johnson's recommendation next week".
"The benefits outweigh the risks"
Production of the Johnson & Johnson vaccine in Baltimore blocked
Covid, Johnson & Johnson: "Stop vaccinations in all clinical trials"
Usa, Fauci: "There will be a decision on the Johnson & Johnson vaccine by Friday"
Share
April 20, 2021 European Medicines Agency (EMA) conclusions on possible links between Johnson & Johnson's coronavirus vaccine and very rare cases of blood clots detected in the United States are expected today.
A press conference is scheduled for 5 pm and will be attended by: the executive director of the EMA, Emer Cooke; the president of the safety committee of the Ema Prac, Sabine Straus; the head of the data analysis and methods task force, Peter Arlett; and as moderator Marie-Agnes Heine, head of the communications department.
Last week J&J decided to delay deliveries of its single-dose vaccines after the U.S. Food and Drug Administration had recommended that authorities pause the use of the remedy pending the investigation of the 6 cases of rare blood clots identified (out of approximately 7 million people immunized in the US with the J&J vaccine).
To European governments, J&J has advised to keep the doses firm pending the EMA guidelines